TICKERNERD
Menu
CERSCERSHealthcare · Medical Devices

CERS Stock Forecast: Cerus Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.81
+0.54% on the day

The 3 Wall Street analysts covering Cerus Corp. hold a median 12-month price target of $5 — +78.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$566.3M
Ticker Nerd rank
90 / 100
Median analyst target
$5.00
Analysts covering
3
Total return, dividends reinvested
1W
−5.9%
1M
−10.1%
YTD
+36.2%
1Y
+133.8%
From 52W high
−14.5%
From 52W low
+137.7%
$1.18
$3.28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CERS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cerus Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
93
Growth
87
Issuance
80
Quality
79
Value
78
Accruals
54
Size
53
Revisions
49
Volatility
31

Momentum (93): The shares have been drifting up relative to others.

Volatility (31): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CERS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CERS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26CERSHigh $5.00Median $5.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $4.00Median $5.00High $5.00

The green dot is the last close — the median target sits +78.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Aug 2026Freedom BrokerInitiatesBuy$6.50
1 May 2026BTIGUpgradeBuy$4.00
1 May 2026BTIGUpgradeBuy—
21 Feb 2025Cantor FitzgeraldReiteratesOverweight—
17 Oct 2024StifelMaintainsBuy—
3 May 2024Cantor FitzgeraldMaintainsOverweight—
12 Apr 2024Craig-HallumInitiatesBuy—
7 Mar 2024Stephens & Co.ReiteratesEqual-Weight—
6 Mar 2024Cantor FitzgeraldReiteratesOverweight—
8 Nov 2023Cantor FitzgeraldAssumesOverweight$9.00 → $3.00
20 Jan 2023BTIGDowngradeNeutral—
27 May 2020StifelMaintainsBuy—
16 Apr 2020Stephens & Co.MaintainsOverweight—
26 Feb 2020BTIGInitiatesBuy—
26 Feb 2020BTIG ResearchInitiatesBuy—
13 Nov 2019BTIGUpgradeBuy—
13 Nov 2019BTIG ResearchUpgradeBuy—
28 Aug 2019StifelInitiatesBuy—
22 Apr 2016BTIGMaintainsBuy—
22 Apr 2016BTIG ResearchMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CERS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CERS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Cerus Corp. (CERS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−35.0×

Cheaper than 97% of US stocks

Price / sales
2.6×

Cheaper than 47% of US stocks

Price / book
8.1×

Cheaper than 13% of US stocks

EV / EBITDA
8901.7×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
9.5%

Higher than 51% of US stocks

Earnings growth (YoY)
9.5%

Higher than 48% of US stocks

Gross margin
51.4%

Higher than 64% of US stocks

Operating margin
−3.2%

Higher than 29% of US stocks

Net margin
−3.1%

Higher than 26% of US stocks

Returns & dividend
Return on equity
−10.8%

Higher than 35% of US stocks

Return on assets
−0.5%

Higher than 41% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CERS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CERSCerus Corp.$566.3M
90
TCMDTactile Systems Technology, Inc.$537.3M
98
SENSSenseonics Holdings, Inc.$506.9M
24
DCTHDelcath Systems, Inc.$591.7M
96
NPCENeuroPace, Inc.$472.3M
90
CTKBCytek Biosciences, Inc.$621.2M
65
SIShoulder Innovations, Inc.$459.3M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cerus Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CERS news & analysis

Cerus: This Blood-Safety Underdog Should Be Earning More Respect

Seeking Alpha · 18 Aug 2026positive

Cerus is shifting toward higher-value therapeutic products while reducing research costs with government funding support. Q2 2026 results showed 10% product revenue growth, a 7% decline in operating expenses, and adjusted EBITDA more than tripling year-over-year, prompting management to raise full-year revenue guidance to $229-231 million for the second time this year.

Why it matters — The revenue guidance raise and improved profitability signal growing commercial momentum and confidence in Cerus's strategic pivot, which CERS watchers would view as a positive development for the company's trajectory.

Cerus Corporation (CERS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 31 July 2026neutral

Cerus Corporation held its Q2 2026 earnings conference call and published the transcript of the event on Seeking Alpha.

Why it matters — Earnings calls provide investors and analysts with key updates on the company's financial performance and strategic outlook.

Cerus Q2 Earnings Call Highlights

MarketBeat · 30 July 2026positive

Cerus reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America and overseas.

Why it matters — The revenue growth and raised outlook signal strengthening demand for Cerus's core blood-safety product line across key markets.

Cerus Corporation Announces Second Quarter 2026 Financial Results

Business Wire · 30 July 2026positive

Cerus Corporation reported its second quarter 2026 financial results and provided a business update, with the CEO highlighting progress in expanding access to safer blood components and expressing satisfaction with the performance of the INTERCEPT Fibrinogen Complex franchise in the U.S.

Why it matters — The quarterly results and business update give Cerus investors a snapshot of the company's operational and financial health, including commentary on key product lines like INTERCEPT Fibrinogen Complex.

FAQ

Frequently asked questions about CERS stock

What is the CERS stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Cerus Corp. have a median 12-month price target of $5, with estimates ranging from $4 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CERS stock a buy right now?

Of the 3 analysts covering Cerus Corp., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cerus Corp. 90 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CERS?

As at 22 Aug 2026, Cerus Corp. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).

Will CERS stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +78.3% from the last close, and Ticker Nerd's factor model ranks Cerus Corp. 90 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CERS stock forecast for 2030?

No analyst covering Cerus Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CERS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $5 over the next 12 months.

How has CERS stock performed over the past year?

Cerus Corp. returned +133.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cerus Corp. do?

Cerus Corporation is a biomedical products company dedicated to enhancing blood transfusion safety through its INTERCEPT Blood System. This platform inactivates a broad range of pathogens, including viruses, bacteria, and parasites, in blood components to reduce the risk of transfusion-transmitted infections.

What is the latest news on CERS?

The most recent item we track (Seeking Alpha, 18 Aug 2026): "Cerus: This Blood-Safety Underdog Should Be Earning More Respect". Cerus is shifting toward higher-value therapeutic products while reducing research costs with government funding support. Q2 2026 results showed 10% product revenue growth, a 7% decline in operating expenses, and adjusted EBITDA more than tripling year-over-year, prompting management to raise full-year revenue guidance to $229-231 million for the second time this year.

Company

About Cerus Corp.

Cerus Corporation is a biomedical products company dedicated to enhancing blood transfusion safety through its INTERCEPT Blood System. This platform inactivates a broad range of pathogens, including viruses, bacteria, and parasites, in blood components to reduce the risk of transfusion-transmitted infections. The INTERCEPT system for platelets and plasma holds both CE mark and FDA approval, making it available to blood centers and hospitals globally, including in the United States, Europe, the Commonwealth of Independent States, the Middle East, and select other regions. In the U.S., the INTERCEPT Blood System for Cryoprecipitation produces Pathogen Reduced Cryoprecipitated Fibrinogen Complex, known as INTERCEPT Fibrinogen Complex, a therapeutic for treating bleeding associated with fibrinogen deficiency in settings like trauma, obstetrics, and surgery. The company operates solely in the blood safety segment, supplying these technologies to support safe blood availability for patients. Founded in 1991 and headquartered in Concord, California, Cerus Corporation plays a vital role in transfusion medicine by providing pathogen-protected platelets, plasma, and fibrinogen products.

CEO Mr. William M. Greenman · 261 employees · United States · https://www.cerus.com